Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs GSK 2256098 (Primary) ; Vismodegib
- Indications Meningioma
- Focus Therapeutic Use
- 19 Apr 2017 Planned number of patients changed from 56 to 69.
- 28 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Aug 2015 New trial record